OBJECTIVE: Most controlled studies comparing second-generation and conventional antipsychotics have focused on the acute treatment of @entity161 . The authors compared symptom outcomes, side effects, and social adjustment in stable @entity161 outpatients who received 2 years of maintenance treatment with @entity1090 or @entity1767 . METHOD: This was a 2-year, randomized, double-blind comparison of 6 mg of @entity1090 versus @entity1767 in 63 @entity1 with stabilized DSM-IV @entity161 . Study @entity1 also received 15 months of standard behavioral skills training or enhanced training with a case manager who promoted @entity1 ' use of their skills in the community. RESULTS: The risk of @entity716 exacerbations and the risk of leaving the study were similar for both drug treatment groups. However, @entity1 who received both @entity1090 and the enhanced community-based skills training were more likely to remain in the study than those in the other treatment groups. @entity1 demonstrated significant improvement in score on the Brief Psychiatric Rating Scale over time with both medications. There were no between-group differences in cluster scores for thought disturbance, hostile-suspiciousness, and @entity3347 . A significant between-group difference favoring @entity1090 was found for the @entity308 cluster. @entity1090 resulted in significantly greater reductions in @entity400 and @entity2146 and greater improvements in most items on the SCL-90-R. CONCLUSIONS: When compared with @entity1 given a low dose of @entity1767 , @entity1090 -treated @entity1 experienced similar improvements in positive and negative symptoms and similar risks of @entity716 exacerbations. However, @entity1090 -treated @entity1 appeared to feel subjectively better, as indicated by less @entity148 and @entity308 and fewer extrapyramidal side effects.

Maintenance treatment of @entity161 with @entity1090 or XXXX : 2-year outcomes.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3347 :: ('MESH:D013375', 'Disease') :: ['withdrawal-retardation'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'anxious-depression'] @entity400 :: ('MESH:D014202', 'Disease') :: ['tremor'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity716 :: ('MESH:D011605', 'Disease') :: ['psychotic'] @entity1767 :: ('MESH:D006220', 'Chemical') :: ['haloperidol'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['akathisia'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone', 'Risperidone']
@entity1767 :: (MESH:D006220,Chemical) :: ['haloperidol']
